Vicept series A raises $16 million
This article was originally published in Scrip
Executive Summary
Vicept Therapeutics, a US speciality biopharmaceutical company focused on rosacea and other skin conditions, has secured a further $10 million to complete a series A round worth $15.8 million in total.